Lorlatinib (Lorbrena)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism, from the NCI Drug Dictionary: An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, lorlatinib is able to cross the blood brain barrier.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

History of changes in FDA indication

History of changes in EMA indication

  • 2019-05-06: Initial conditional approval as Lorviqua

History of changes in Health Canada indication

  • 2019-02-22: Initial notice of compliance with conditions
  • 2022-05-20: Conditions were met

History of changes in PMDA indication

  • 2018-09-21: Conditional new approval for the treatment of unresectable or recurrent anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer with resistance or intolerance to ALK tyrosine kinase inhibitors.
  • 2021-11-25: New indication for the treatment of unresectable or advanced/recurrent anaplastic lymphoma kinase (ALK) fusion gene-positive non-small cell lung cancer.

Patient Drug Information

Also known as

  • Code name: PF-06463922
  • Brand name: Lorbrena, Lorviqua